Ground Swell Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ground Swell Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$2K	Buy	+200	New	+$2.45K	﹤0.01%	1867

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Ground Swell Capital's BCRX Position: Q3 2014 in Review

Ground Swell Capital opened a new position in BioCryst Pharmaceuticals (BCRX) in Q3 2014: 200 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #1867 among its holdings.

102 funds tracked by Wall St. Rank hold BCRX as of Q3 2014.

Ground Swell Capital held 200 shares of BioCryst Pharmaceuticals worth $2K as of Q3 2014.
BioCryst Pharmaceuticals was a new Ground Swell Capital position in Q3 2014.
BioCryst Pharmaceuticals made up ﹤0.01% of Ground Swell Capital's portfolio in Q3 2014, its #1867 holding.
102 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.